Semaglutide denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Semaglutide for Medical Necessity — and How to Build Your Appeal

Medical-necessity denials are the most common type of coverage refusal for semaglutide, and they are among the most successfully appealed when the clinical record is organized and complete. BCBS's determination that semaglutide is not medically necessary does not mean your doctor is wrong — it means the documentation submitted so far did not satisfy every criterion in the plan's coverage policy.

## Why This Denial Happens

BCBS evaluates medical necessity against its own internal coverage criteria, which are drawn from — but not identical to — the FDA-approved prescribing information and professional clinical guidelines. Common gaps that trigger denials include: the clinical record does not clearly document the severity of the underlying condition; prior treatments tried and failed are not itemized with dates and outcomes; or the prescriber's notes do not explicitly address each criterion BCBS requires. The solution is systematic documentation, not a different drug.

## Your Federal Appeal Rights

• Internal appeal: File within 180 days of the denial notice. BCBS must issue a standard decision within 30–60 days and an expedited decision within 72 hours.
• External review (ACA §2719): If BCBS upholds the denial internally, you have approximately 4 months from the final internal denial to request independent external review. The independent reviewer applies clinical standards and is not bound by BCBS's policy definitions.
• ERISA §503: Employer self-funded plans are subject to full-and-fair review; federal court is a backstop.
• Expedited option: If your condition is urgent, request expedited internal appeal and simultaneous expedited external review.

## Documentation to Gather

1. Diagnosis confirmation: Chart notes, diagnostic test results, and specialist records confirming the diagnosis for which semaglutide is prescribed, with dates. 2. Clinical severity record: Objective documentation of how your condition affects your health and functioning — lab results (without asserting specific threshold numbers in your appeal letter), body measurements, relevant assessments recorded in your chart. 3. Prior-treatment history: A chronological list of every treatment tried before semaglutide, with start dates, stop dates, prescribed regimens, and documented outcomes (inadequate response, adverse effects, contraindications). 4. Prescriber medical-necessity letter: This is the most important document. Your prescriber should walk through each of BCBS's coverage criteria one by one and match each to a specific chart finding, citing the FDA-approved prescribing information for semaglutide and the applicable guideline organization (e.g., the ADA or relevant obesity-medicine society) without asserting specific cutoff numbers.

## Criteria-Mapping Structure

Request BCBS's full medical/coverage policy for semaglutide. Copy each criterion into a table and answer it with the precise chart fact:

| BCBS Coverage Criterion | Supporting Chart Evidence | |---|---| | [Paste criterion verbatim from policy] | [Chart note, date, provider, and finding] | | [Prior-therapy requirement] | [Drug name, dates, documented outcome] | | [Diagnosis/indication requirement] | [ICD-10 code, diagnostic record, date confirmed] |

Attach all exhibits with a numbered index. The cover letter should name each criterion, state how it is met, and request review by a board-certified specialist in the relevant area.